NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement

Compliance with Nasdaq Listing Requirements - The company regained compliance with the Nasdaq Capital Market's minimum market value of listed securities (MVLS) requirement, which mandates a MVLS of at least $35 million for 10 consecutive trading days [1][2] - The company's MVLS was at least$35 million for 10 consecutive trading days, meeting the requirement on January 16, 2025 [2] - The Nasdaq Listing Qualifications Staff confirmed the matter is now closed [1][6] Company Overview and Pipeline - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [3] - The company's lead product, NRX-101, is an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain, with potential as a non-opioid treatment for chronic pain and complicated UTI [3] - NRx is preparing to file a New Drug Application (NDA) for Accelerated Approval of NRX-101 for bipolar depression and suicidality or akathisia [3] Recent Developments in Drug Development - NRx announced the initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on clinical trial results from the US National Institutes of Health and data from French health authorities [4] - The US FDA granted Fast Track Designation for the development of ketamine (NRX-100) as part of a protocol to treat patients with acute suicidality [4] Contact Information - Matthew Duffy, Chief Business Officer of NRx Pharmaceuticals and Co-Chief Executive Officer of HOPE Therapeutics, is the contact for further information [8]